Study of the Treatment of Articular Repair (STAR)

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This study is a prospective, longitudinal, multi-center, within patient evaluation of patients with articular cartilage defects of the knee who have had an inadequate response to a prior non-Carticel surgical treatment. Patients who met eligibility criteria were enrolled in the study. Subsequent to implantation with Carticel patients have follow-up every 6-months up to 48-months.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00140634` - The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients
	Not yet recruiting	`NCT06451120` - Platelet Rich Plasma Injections In Young And Old Human Subjects	Phase 2

NCT number	NCT00158613
Study type	Interventional
Source	Vericel Corporation
Contact
Status	Completed
Phase	Phase 4
Start date	March 2000
Completion date	November 2005

Study of the Treatment of Articular Repair (STAR)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms